<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00137774</url>
  </required_header>
  <id_info>
    <org_study_id>04-272</org_study_id>
    <nct_id>NCT00137774</nct_id>
  </id_info>
  <brief_title>Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors</brief_title>
  <official_title>A Phase II Study of Bevacizumab in Combination With Temozolomide in Patients With Advanced Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine what effects (good and bad) bevacizumab and&#xD;
      temozolomide have on patients with neuroendocrine tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive temozolomide orally once daily for one week, followed by a one-week&#xD;
      rest period. This one-week on/one week off schedule will continue for the duration of&#xD;
      treatment unless significant side effects develop.&#xD;
&#xD;
      Bevacizumab will be administered intravenously every other week. After eight weeks (two&#xD;
      cycles), a CT scan will be performed to see how treatment affected tumor growth.&#xD;
&#xD;
      Bactrim, an antibiotic, and acyclovir, an antiviral medicine, will be given in order to help&#xD;
      prevent infection.&#xD;
&#xD;
      Blood tests will be done every other week to evaluate any side effects.&#xD;
&#xD;
      Once the study has been completed, a physical exam, vital signs, blood tests, and CT scan&#xD;
      will be performed.&#xD;
&#xD;
      Patients will remain on the study as long as they continue to receive benefit from the&#xD;
      treatment and there are no serious side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the response to bevacizumab in combination with temozolomide in patients with metastatic neuroendocrine tumors</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the time to progression, progression free survival and safety of bevacizumab in combination with temozolomide in this patient population</measure>
  </secondary_outcome>
  <enrollment type="Actual">34</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically documented locally unresectable or metastatic neuroendocrine tumor&#xD;
             excluding small cell carcinoma&#xD;
&#xD;
          -  Measurable disease &gt; 1cm by spiral computed tomography (CT) or &gt; 2cm by other&#xD;
             radiographic technique&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  Life expectancy of &gt; 12 weeks&#xD;
&#xD;
          -  Prior treatment with chemotherapy is allowed&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0mg/dl&#xD;
&#xD;
          -  AST &lt; 5x upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum creatinine &lt; 2.0mg/dl&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm3&#xD;
&#xD;
          -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
          -  International Normalized Ratio (INR) &lt; 1.5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with temozolomide, decarbazine or bevacizumab&#xD;
&#xD;
          -  Clinically apparent central nervous system metastases or carcinomatous meningitis&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Major surgery, open biopsy, or significant traumatic injury within 28 days&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Chronic, daily treatment with aspirin or nonsteroidal anti-inflammatory medication&#xD;
&#xD;
          -  Serious, nonhealing wound, ulcer or bone fracture&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  History of other disease or metabolic dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew H. Kulke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Insitute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012 Aug 20;30(24):2963-8. doi: 10.1200/JCO.2011.40.3147. Epub 2012 Jul 9.</citation>
    <PMID>22778320</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>April 7, 2013</last_update_submitted>
  <last_update_submitted_qc>April 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Matthew H. Kulke, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Metastatic Neuroendocrine Tumor</keyword>
  <keyword>Advanced Neuroendocrine tumor</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

